Friday, November 08, 2013 8:28:40 AM
There are innumerable new technologies with fabulous potential in animal studies. But there have been hundreds of drugs that cured cancer in mice and were useless in humans
The difference with nanoviricides is that, because they do not require any interaction with the host for their antibiotic effect, the animal studies will be far more representative than usual. But THAT is the kind of exception that PB executives are highly reluctant to make. It's bad enough if you make what appears to be a sound decision but it nevertheless goes wrong. But should you make a decision based on an EXCEPTION and THAT goes wrong: OFF WITH THE HEAD!
That kind of thinking is exactly why BPs cant come up with new drug approaches themselves. It would be foolish to expect them to go into a mode of thinking at the opposite end of the spectrum when evaluating possible buys.
BP is not going to attempt a buyout before Phase I/IIa at the very earliest and in that case only if the data supports an early approval IMHO. Otherwise Phase II is the earliest.
In any case I doubt that Dr Seymour would ever want to sell to BP before at least several drugs were on the market, because he would get a vastly higher price then AND because it should only take several additional years to get there.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM